Albany, NY -- (SBWIRE) -- 07/06/2017 -- Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone fragility and threat of bone cracks and fractures. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. The osteoporosis drugs market report studies the current scenario as well as the future market potential for osteoporosis drugs globally. The disease overview section of the report provides a brief introduction of osteoporosis along with causes, diagnosis, symptoms and management methodology. The market for osteoporosis drugs has been segmented on the basis of drug classes used to treat the disease. The market for these drug classes has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence, pipeline drug candidates, patents and global impact on sales of the drugs (along with the class) after patent expiry. Based on drug class, the market is divided into bisphosphonates, calcitonin, RANK Ligand Inhibitors (denosumab), parathyroid hormone therapy (PTH), selective estrogen receptor modulators (SERMs) and others (estrogen therapy and vitamin D - calcium). Bisphosphonates is the largest and established drug class. However, the entire class is driven by generic products. Hence, market share of this class is expected to decrease during the forecast period from 2014 to 2020. In addition, new drug classes such as RANK Ligand Inhibitors and PTH are considered as important contributors in the market. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are also forecasted from the expected year of approval. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2012 to 2020, considering 2013 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2014 to 2020.

Request For Sample Report: http://www.mrrse.com/sample/945

Geographically, the osteoporosis drugs market has been segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2012 to 2020, along with the CAGR (%) for the forecast period 2014 to 2020. The geographical study is mainly based on various regional parameters, such as, prevalence of the disease in particular region, technological utilization, presence of key players, and other domestic factors. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five forces analysis, market attractiveness analysis, event impact analysis and value chain analysis. These different analyses would provide a thorough understanding about the market from its past, present and future perspectives and help market players to design effective business strategies. The market overview section of the report also includes the competitive landscape of the market wherein market share analysis of leading players in the global osteoporosis drugs market, in terms of percentage share in 2013, has been discussed. This analysis would help established players to penetrate the market. Market attractiveness analysis would help the market player to understand the level of attractiveness of various regions of the world, estimated on various parameters such as size, raw materials, competition and others.

A list of recommendations has also been included for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report concludes with the profiles of major players in the global osteoporosis drugs market such as Actavis plc, Amgen, Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd., Merck & Co, Inc., Novartis International AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. 

Osteoporosis Drugs Market, by Drug Class
Bisphosphonates
Parathyroid Hormone Therapy (PTH) Drugs
Selective Estrogen Receptor Modulators (SERMs)
RANK Ligand Inhibitors
Calcitonin
Others (Vitamin D, Calcium)
Pipeline Analysis

Browse Full Reports With TOC : http://www.mrrse.com/osteoporosis-drug-market

Osteoporosis Drugs Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Related Report :Pharmaceutical Membrane Filtration Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 - 2020

Electrophoresis Reagents Market - Global Industry Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 - 2020

Dietary Supplements Market: Global Industry Analysis and Opportunity Assessment, 2015 – 2025

About MRRSE
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. 

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE's repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact
State Tower 
90, State Street 
Suite 700 
Albany, NY - 12207 
United States
Telephone: +1-518-730-0559 
Email: sales@mrrse.com
Google+: https://plus.google.com/u/0/109558601025749677847/posts
Linked in: https://www.linkedin.com/company/mrrse
Twitter: https://twitter.com/MRRSEmrrse